Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

Parker Institute backs an upstart biotech looking to develop a new, convertible CAR-T

Source: 
Endpoints
snippet: 

The billionaire-backed Parker Institute for Cancer Immunotherapy is investing and partnering with a biotech their researchers believe has the potential to develop a new-model CAR-T that can be better guided down narrow pathways and equipped with a convenient on/off switch to help avoid any fatal accidents.